Skip to main content
. 2019 Oct 3;14(10):e0223530. doi: 10.1371/journal.pone.0223530

Fig 2. Network of eligible comparisons.

Fig 2

The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments. TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.